RecruitingPhase 2NCT06577909

Prednisone Plus IVIg vs. Prednisone for ITP During Pregnancy

Prednisone Plus IVIg Compared With Prednisone for Immune Thrombocytopenia During Pregnancy

Sponsor

Peking University People's Hospital

Enrollment

100 participants

Start Date

Oct 19, 2023

Study Type

INTERVENTIONAL

Conditions

Immune Thrombocytopenia

Summary

This is a prospective, randomized, open-label, multicenter clinical trial study to compare the efficacy and safety of prednisone plus IVIg to prednisone monotherapy in the treatment of immune thrombocytopenia (ITP) in pregnancy.

Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 50 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called IVIg and a drug called Prednisone for people with immune thrombocytopenia. The study is currently recruiting participants at 1 location. People eligible for this study include women aged 18 Years to 50 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPrednisone

Prednisone po, 20mg per day for 4 weeks, if response (Plt 30-100×100\^g/L), gradually taper to the maintenance dose of 5-10mg per day until 6 weeks after delivery; if not response, gradually taper to withdrawal.

DRUGIVIg

IVIg 400mg/kg (≤20g for the total dose) per day for 5 days, and repeated in the case of lack of response by day 14

Locations(1)

Peking University Insititute of Hematology, Peking University People's Hospital

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06577909

Related Trials

Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders

NCT0710456540 locations

Contribution of Anti-platelet Antibodies Identified With MAIPA Assay in the Demonstration of the Auto-immune Character of a Thrombocytopenia at Diagnosis

NCT048004581 location

Phase I Study of SHR-2173 Injection in Patients With Primary Immune Thrombocytopenia

NCT072067581 location

Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment

NCT0700796230 locations

Safety and Efficacy of GL-2045 in Patients With Immune Thrombocytopenia

NCT076058451 location